Lakefront Biotherapeutics American Depositary Shares
LKFT
78 hedge funds and large institutions have $922M invested in Lakefront Biotherapeutics American Depositary Shares in 2017 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 31 increasing their positions, 14 reducing their positions, and 9 closing their positions.
156% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 9
121% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 14
22% more funds holding
Funds holding: 64 → 78 (+14)
6% more capital invested
Capital invested by funds: $868M → $922M (+$54.4M)
1.93% more ownership
Funds ownership: 21.76% → 23.69% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
61% less call options, than puts
Call options by funds: $260K | Put options by funds: $675K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
+$180M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$30.9M |
| 3 |
Renaissance Technologies
New York
|
+$13M |
| 4 |
Jane Street
New York
|
+$10M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$8.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$89.7M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$10.3M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$8.14M |
| 4 |
DM
Deerfield Management
New York
|
-$6.08M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.16M |
LKFT Hedge Fund Activity: Q2 2017 in Review
78 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q2 2017, worth a combined $922M — up 6.3% from $868M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new LKFT positions and 9 closed out — a net gain of 14 holders — while 31 added to existing stakes and 14 trimmed.
The largest buyer was Sands Capital Management, opening a new position worth an estimated $180M. The largest seller was Fidelity Investments, cutting an estimated $89.7M.
- 78 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q2 2017, up from 64 in Q1 2017.
- Funds reported $922M of Lakefront Biotherapeutics American Depositary Shares stock for Q2 2017, up 6.3% quarter-over-quarter.
- 23 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q2 2017 and 9 closed out, a net change of +14 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q2 2017 was Sands Capital Management, an estimated $180M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q2 2017 was Fidelity Investments, an estimated $89.7M sold.
Based on aggregated 13F filings for Q2 2017.